List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rhinovirus Infections - Overview
Rhinovirus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rhinovirus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhinovirus Infections - Companies Involved in Therapeutics Development
Apollo Therapeutics LLC
Arum Therapeutics Inc
AstraZeneca Plc
Biological Mimetics Inc
Celestial Therapeutics Inc
Collaborations Pharmaceuticals Inc
Ena Respiratory Pty Ltd
Enyo Pharma SA
G.ST Antivirals GmbH
Gilead Sciences Inc
Haplogen GmbH
Harbins Ruhr Bioscience Inc
Kyorin Pharmaceutical Co Ltd
Meissa Vaccines Inc
PrEP Biopharm Ltd
Romark Laboratories LC
Sagimet Biosciences
Secarna Pharmaceuticals GmbH & Co KG
ST Pharm Co Ltd
Symmune Therapeutics LLC
Viravaxx AG
Rhinovirus Infections - Drug Profiles
2-DG - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ART-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNT-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Enterovirus Infections and Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Rhinovirus and Coxsackievirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human rhinovirus (polyvalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INNA-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPRA-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polymer for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rhinovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLA2G16 for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sphingosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVB-3567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rhinovirus Infections - Dormant Projects
Rhinovirus Infections - Discontinued Products
Rhinovirus Infections - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Meissa announces award of NIH SBIR grant to support development of multivalent human rhinovirus vaccine candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Rhinovirus Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Rhinovirus Infections - Pipeline by Apollo Therapeutics LLC, 2021
Rhinovirus Infections - Pipeline by Arum Therapeutics Inc, 2021
Rhinovirus Infections - Pipeline by AstraZeneca Plc, 2021
Rhinovirus Infections - Pipeline by Biological Mimetics Inc, 2021
Rhinovirus Infections - Pipeline by Celestial Therapeutics Inc, 2021
Rhinovirus Infections - Pipeline by Collaborations Pharmaceuticals Inc, 2021
Rhinovirus Infections - Pipeline by Ena Respiratory Pty Ltd, 2021
Rhinovirus Infections - Pipeline by Enyo Pharma SA, 2021
Rhinovirus Infections - Pipeline by G.ST Antivirals GmbH, 2021
Rhinovirus Infections - Pipeline by Gilead Sciences Inc, 2021
Rhinovirus Infections - Pipeline by Haplogen GmbH, 2021
Rhinovirus Infections - Pipeline by Harbins Ruhr Bioscience Inc, 2021
Rhinovirus Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, 2021
Rhinovirus Infections - Pipeline by Meissa Vaccines Inc, 2021
Rhinovirus Infections - Pipeline by PrEP Biopharm Ltd, 2021
Rhinovirus Infections - Pipeline by Romark Laboratories LC, 2021
Rhinovirus Infections - Pipeline by Sagimet Biosciences, 2021
Rhinovirus Infections - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021
Rhinovirus Infections - Pipeline by ST Pharm Co Ltd, 2021
Rhinovirus Infections - Pipeline by Symmune Therapeutics LLC, 2021
Rhinovirus Infections - Pipeline by Viravaxx AG, 2021
Rhinovirus Infections - Dormant Projects, 2021
Rhinovirus Infections - Discontinued Products, 2021

List of Figures
Number of Products under Development for Rhinovirus Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned
• Apollo Therapeutics LLC
• Arum Therapeutics Inc
• AstraZeneca Plc
• Biological Mimetics Inc
• Celestial Therapeutics Inc
• Collaborations Pharmaceuticals Inc
• Ena Respiratory Pty Ltd
• Enyo Pharma SA
• G.ST Antivirals GmbH
• Gilead Sciences Inc
• Haplogen GmbH
• Harbins Ruhr Bioscience Inc
• Kyorin Pharmaceutical Co Ltd
• Meissa Vaccines Inc
• PrEP Biopharm Ltd
• Romark Laboratories LC
• Sagimet Biosciences
• Secarna Pharmaceuticals GmbH & Co KG
• ST Pharm Co Ltd
• Symmune Therapeutics LLC
• Viravaxx AG